Preliminary evidence of glycine as a biomarker of cardiovascular disease risk in children with obesity
Authors' conclusion
Given that CVD progression is a continuum and the disease itself is not present in children and biomarkers are typically used to monitor CVD in children, the links between GLY and biomarkers of CVD provide evidence for the first time of a potential role for GLY in CVD in children with obesity.
Study context
- Population
- Male and female adolescents aged 14–18 years, Tanner stage >IV, with normal weight or obesity
- Participants
- 6 vs 15
- Exposure
- Normal weight vs obesity
- Normal weight (NW)n = 6reference
- Obesity (OB)n = 15
- Outcome
- Associations of circulating glycine (GLY) with biomarkers of cardiovascular disease (CVD)
Methodological detailsGlycine (GLY), branched chain amino acids (BCAA), 25(OH)D, glucose, insulin, adiponectin, high sensitivity C-reactive protein (hs-CRP) and IL-6 measured; body composition by DXA; Homeostatic model assessment for insulin resistance (HOMA-IR) calculated
- GLY, BCAA, 25(OH)D, glucose, insulin, adiponectin, hs-CRP and IL-6 measured; body composition by DXA; HOMA-IR calculated
Main finding
As reported in the abstract
Associations of GLY with CVD biomarkers
- GLY vs visceral fat, r2
- 0.40
- GLY vs BCAA, r2
- 0.44
- GLY vs HOMA-IR, r2
- 0.33
- GLY vs 25(OH)D, r2
- 0.48
- GLY vs IL-6, r2
- 0.46
- GLY vs adiponectin, r2
- 0.39
Observational data: associations, not effects.
Original publication
Preliminary evidence of glycine as a biomarker of cardiovascular disease risk in children with obesity. Int J Obes (Lond). Published 29 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →